The post-acquisition layoffs have begun at Dendreon, with 77 employees losing their jobs. Assets of Seattle-based Dendreon were purchased out of… Read More
Dendreon, the once-promising Seattle biotechnology company that developed treatments for prostate cancer, will be sold to Quebec-based Valeant Pharmaceuticals International Inc.… Read More
Dendreon, a once-promising Seattle biotech company developing treatments for prostate cancer, today filed for Chapter 11 bankruptcy protection. It marks… Read More
Slower-than-expected uptake of its Provenge prostate cancer drug forced Seattle biotech company Dendreon to announce 500 job cuts this afternoon,… Read More
Elizabeth Wheden, a marketing industry veteran who previously worked at Razorfish and Wunderman, has joined Seattle’s Marketfish as director of… Read More
